Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904604 · ClinicalTrials.gov registry record · Phase 2
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT01904604 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 75 participants.
The verdict
NCT01904604, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
Food allergy occurs when the immune system reacts against foods. The immune system is the part of the body that protects us from illness and germs, but it can also cause allergies. Peanut allergy occurs in 1 - 2% of people in the United States and other Western countries. There is proof that allergy to peanut is increasing. Allergic reactions to peanut can be severe and life threatening. The only way that you can prevent an allergic reaction is to avoid exposure to peanuts. However, peanut proteins are found in a variety of foods and people can be accidently exposed to peanut proteins. Treatment for accidental exposure include antihistamines (medications like Benadryl), and injectable epinephrine (adrenalin) which must be carried at all times. DBV Technologies has developed an epicutaneous delivery system, a patch that puts the peanut protein on the skin.
Interventions
- BIOLOGICAL Placebo Viaskin® Patch
- BIOLOGICAL Low-dose DBV712 Viaskin® Patch
- BIOLOGICAL High-dose DBV712 Viaskin® Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2013-09 |
| Est. Completion | 2018-08-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01904604
The ClinicalTrials.gov registry entry for NCT01904604 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Viaskin® Patch is the first listed.
NCT01904604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01904604 about?
NCT01904604 is a clinical study titled "Peanut Epicutaneous Phase II Immunotherapy Clinical Trial". Food allergy occurs when the immune system reacts against foods. The immune system is the part of the body that protects us from illness and germs, but it can also cause allergies. Peanut allergy occurs in 1 - 2% of people in the United States and other Western countries. There is proof that allergy...
What is the current status of trial NCT01904604?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2013-09. Estimated completion is 2018-08-21.
What interventions are being tested in trial NCT01904604?
The interventions under investigation include: Placebo Viaskin® Patch (BIOLOGICAL), Low-dose DBV712 Viaskin® Patch (BIOLOGICAL), High-dose DBV712 Viaskin® Patch (BIOLOGICAL).
Who is sponsoring clinical trial NCT01904604?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.